Document:

<PAGE>   1
                                                                   EXHIBIT 10.17

               MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
                           TECHNOLOGY LICENSE CONTRACT

                     ARTICLE 1.00 - PRELIMINARY PROVISIONS.

1.01  DATE.  The effective date of this contract is the 26th day of May, 2000.

1.02  PARTIES.  There are two parties to this contract.  They are:

(a)      MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH, a Minnesota
         charitable corporation, located at 200 First Street SW, Rochester,
         Minnesota 55905-0001 (called "MAYO" in this contract), and

(b)      GMP|Cardiac Care, Inc., a Delaware corporation with its principal place
         of business at One East Broward Boulevard, Suite 1701, Fort Lauderdale,
         FL 33301 (called the "COMPANY" in this contract).

1.03 PURPOSE OF CONTRACT. Certain inventions have been made in connection with
MAYO's research, patient care and education programs. By assignment of the
inventions from the inventors, MAYO owns certain patent-rights and know-how.
MAYO intends to grant licenses to use its patent rights and know-how for the
development of products, processes and methods for public use and benefit. The
COMPANY intends to develop marketable products, processes and methods for public
use and benefit within the Territory described in this contract, by using the
Licensed Rights and Licensed Know-How. Both parties acknowledge that MAYO has
carefully selected the COMPANY because of the COMPANY's unique characteristics
that make the COMPANY especially suitable as a licensee of the inventions. The
COMPANY enters this licensing contract with MAYO for use of the Licensed Rights
and Licensed Know-How on an exclusive basis, subject only: (a) to MAYO's right
to make, have made, and use the Licensed Rights and Know-How on a royalty-free
basis within its and its Affiliates' own non-commercial research programs; and
(b) to the rights, if any, of the United States government. For purposes of this
paragraph, non-commercial research programs shall exclude research programs that
use the Licensed Rights and Licensed Know-How to perform clinical research for a
for-profit organization, to produce or manufacture products for general sale, or
to perform services for a fee. The parties believe that the only
commercially-practical way of developing products and processes for public use
and benefit using the Licensed Rights and Know-How is an exclusive licensing
arrangement.

                           ARTICLE 2.00 - DEFINITIONS.

2.01 AFFILIATE means a legal entity controlled by, or controlling, another legal
entity, or which is an Affiliate of an Affiliate, or an Affiliate of an
Affiliate of an Affiliate. "Control" means direct or indirect beneficial
ownership of at least fifty (50) percent of the voting stock of a corporation;
direct or indirect ownership of at least fifty (50) percent of the income of a
legal entity; or possession of at least fifty (50) percent of the voting rights
of the members of a nonprofit or nonstock corporation. MAYO's Affiliates
include, but are not limited to: Mayo Foundation; Rochester Methodist Hospital;
Saint Mary's Hospital; Mayo Clinic Jacksonville, Florida; St. Luke's Hospital,
Jacksonville, Florida; Mayo Clinic Arizona; Mayo Clinic Hospital, Arizona; Mayo
Regional Practices, P.C., Decorah, Iowa; and Mayo Regional Practices of
Wisconsin, Ltd.

2.02 COMBINATION PRODUCT means a product that includes a Licensed Product sold
in combination with another component(s) the manufacture, use or sale of which
by an unlicensed party would not constitute an infringement of the Licensed
Rights under this contract (the "Unlicensed

                                       1
<PAGE>   2

Component(s)").

2.03 FIELD OF USE means all diagnostic, scientific, forensic and therapeutic
applications and all equipment, materials, devices and/or services that provide
or perform such functions.

2.04 LICENSE QUARTER begins on the date in Section 1.01 of this contract, and
thereafter begins on the first day of each January, April, July, and October
during the term of this contract.

2.05 LICENSE YEAR begins on the date in Section 1.01 of this contract, and
thereafter begins on the first day of each January during the term of this
contract.

2.06 LICENSED KNOW-HOW means trade secrets including technical information,
whether or not patentable, including but not limited to engineering, scientific,
and practical information and formulas; information about qualities, uses, and
sales methods and procedures; information about materials and sources;
blueprints, drawings, specifications, and other relevant writings used in the
design, manufacture, and sale of products, processes, and methods in connection
with the Licensed Rights and Licensed Products.

2.07 LICENSED PRODUCTS means any device or other product, the manufacture, use,
import, offer to sell or sale of which would constitute, but for the license
granted to the COMPANY pursuant to this contract, an infringement of a valid
claim of Licensed Rights (infringement shall include, but is not limited to,
direct, contributory or inducement to infringe).

2.08 LICENSED RIGHTS means:

           (a) the United States, international and foreign patents listed on
               Exhibit A as of the date hereof;
           (b) the United States, international and foreign patent applications
               and/or provisional applications listed on Exhibit A and the
               resulting patents;
           (c) any patent applications resulting from the provisional
               applications or disclosures listed on Exhibit A, and any
               divisionals, continuations-in-part applications, and continued
               prosecution applications (and their relevant international or
               foreign equivalents) of the patent applications listed on Exhibit
               A and of such patent applications that result from the
               provisional applications or disclosures listed on Exhibit A, to
               the extent the claims are directed to subject matter specifically
               described in the patent applications or disclosures listed on
               Exhibit A, and the resulting patents;
           (d) any patents resulting from reissues, reexaminations, or
               extensions (and their relevant international equivalents) of the
               patents described in (a), (b) and (c) above;
           (e) international (non-United States) patent applications and
               provisional applications filed after the date of this Agreement
               and the relevant international equivalents to divisionals,
               continuations, continuation-in-part applications and continued
               prosecution applications of the patent applications to the extent
               the claims are directed to subject matter specifically described
               in the patents or patent applications referred to in (a), (b),
               (c) and (d) above and the resulting patents; and
           (f) all future patent applications having claims that are
               improvements or enhancements to the inventions disclosed and
               claimed in patent applications and patents listed on Exhibit A
               and any corresponding foreign patent applications and any
               patents, patents of addition, or other equivalent foreign patent
               rights issuing, granted or registered thereon arising out of or
               in connection with research at MAYO sponsored by the COMPANY
               (collectively, "Related

                                       2
<PAGE>   3

               Improvements").

2.09 MATERIAL BREACH means breaches of this contract which are specified in this
contract as being material breaches, and in addition any breach of this contract
which the non-breaching party in the exercise of its good-faith discretion
determines is so injurious to the relationship between the parties that this
contract should be liable to immediate Termination.

2.10 MAYO INFORMATION means all information embodied in the Licensed Rights and
Licensed Know-How or expressly marked, labeled, referenced in writing, or
otherwise designated by MAYO as confidential, which is disclosed to the COMPANY
by MAYO, relating in any way to MAYO's markets, customers, patents, inventions,
products, procedures, designs, plans, organization, employees, or business in
general, but not including:

         (a)  information that becomes part of the public domain through no
              action or fault of the COMPANY; or

         (b)  information that the COMPANY can show by sufficient proof was in
              its possession before disclosure by MAYO to the COMPANY and was
              not acquired, directly or indirectly, from MAYO; or

         (c)  information that was received by the COMPANY from a third party
              having a legal right to transmit such information; or

         (d)  information that is independently developed by the COMPANY without
              the benefit of the MAYO Information.

2.11 NET SALES means gross sales revenues received by the COMPANY or the
COMPANY's Affiliates from their sale of Licensed Products, less trade discounts
allowed, refunds, returns and recalls, sales taxes, freight, storage and
delivery costs, discounts or rebates accrued, incurred or paid to Federal
Medicaid or State Medicare or other payers, amounts exactly repaid or credited
by reason of rejections or the return of Licensed Products (due to recalls,
dating or other reasons), and any other reasonable customary deductions that
according to generally accepted accounting principle ("GAAP") are bona fide
deductions from gross sales to determine net sales. Net Sales do not include any
monies received by the Company or its affiliated companies from sublicensees.

2.12 SUBLICENSE REVENUES means all monies received by the Company or its
affiliated companies from a sublicensee for sales of Licensed Products, by,
through, or under a sublicensee.

2.13 TERMINATION of this contract means the ending, expiration, rescission, or
any other discontinuation of this contract for any reason whatsoever.

2.14 TERRITORY means the world.

                         ARTICLE 3.00 - GRANT OF RIGHTS.

3.01 GRANT. Subject only to the exceptions described in Section 1.03 of this
contract, MAYO grants to the COMPANY an exclusive license to make, have made,
use, modify, enhance, import or have imported, and sell or have sold the
Licensed Products, and to use the Licensed Rights and Licensed

                                       3
<PAGE>   4
*** CONFIDENTIAL INFORMATION OMITTED AND FILED SEPARATELY WITH THE SECURITIES
    AND EXCHANGE COMMISSION. ASTERISKS DENOTE SUCH OMISSIONS.

Know-How in connection therewith, in the Territory within the Field of Use,
according to the terms of this contract. The Licensed Rights and Licensed
Know-How, if not patented, are trade secrets of MAYO.

3.02  PURCHASE AT COST.  MAYO may, at its sole option, purchase the Licensed
Products in any quantity for use at the best priced offered by COMPANY for
commercial use for the quantities ordered.

3.03 DISCLOSURE OF KNOW-HOW. Within a reasonable time after execution of this
contract, and from time to time, MAYO shall make available to the COMPANY the
Licensed Know-How. MAYO, however, owns the materials in which the Licensed
Know-How is embodied, including, but not limited to, prototypes, blueprints, and
plans. The COMPANY shall have the right to engage the inventors to assist in the
commercialization of the Licensed Rights for such reasonable periods and at such
times and upon such other terms that are mutually acceptable to the inventors
and the COMPANY.

3.04 CONFIDENTIALITY. The COMPANY acknowledges that all MAYO Information is
confidential and proprietary to MAYO. The COMPANY agrees not to use any MAYO
Information during the term of this contract, and for three (3) years after the
Termination of this contract, for any purpose other than as permitted under this
contract and in connection with its exercise of its rights with regard to the
Licensed Rights and Licensed Products. Except as required by governmental orders
or as deemed necessary by its counsel for compliance with governing laws and
regulations, the COMPANY also agrees not to disclose or to provide any MAYO
Information to any third party for any purpose other than as licensed, permitted
or required under this contract as to the COMPANY, and to take all reasonable
measures to prevent any such disclosure by its employees, agents, contractors,
or consultants during the term of this contract, and for three (3) years after
its Termination.

       (a)   At MAYO's request, the COMPANY shall cooperate fully with MAYO,
             except financially, in any legal actions taken by MAYO to protect
             its rights in the Licensed Know How and in the MAYO Information.

       (b)   Any material violation of the COMPANY's obligations stated in this
             Section 3.04 is a Material Breach of this contract.

3.05 SUBLICENSES. The COMPANY shall have the right to sublicense its rights
granted under Section 3.01 above to third parties provided that such entities
are subject to the same limitations and restrictions imposed upon the COMPANY
hereunder. MAYO agrees to promptly review any such proposed agreement and
confirm in writing that such proposal meets the requirements described in the
preceding sections, or if it does not, to describe the changes necessary to
cause it to conform.

                   ARTICLE 4.00 - CONSIDERATION AND ROYALTIES.

4.01 CONSIDERATION. Promptly upon execution of this contract, the COMPANY shall
pay MAYO an up-front royalty of [***] as consideration for entering into the
contract. This initial royalty is nonrefundable and is not an advance against
any royalties otherwise due under this contract.

4.02  FEES AND ROYALTIES.

         (a)      The Company shall pay to MAYO a [***] royalty fee on the
                  first anniversary of the

                                       4
<PAGE>   5
*** CONFIDENTIAL INFORMATION OMITTED AND FILED SEPARATELY WITH THE SECURITIES
    AND EXCHANGE COMMISSION. ASTERISKS DENOTE SUCH OMISSIONS.

                  execution of this contract.

         (b)      The Company shall pay to MAYO a [***] royalty fee on the
                  second anniversary of the execution of this contract.

         (c)      The Company shall pay to MAYO a royalty fee of [***] within
                  thirty (30) days of Company receiving regulatory approval for
                  the first Licensed Product from the U.S. Food and Drug
                  Administration ("FDA").

         (d)      The Company shall pay to MAYO a royalty fee of [***] within
                  thirty (30) days of Company receiving regulatory approval of
                  the first stent Licensed Product from the FDA.

         (e)      The Company shall pay to MAYO a royalty fee of [***] upon
                  successful completion of the FDA phase 3 clinical trials for
                  the first stent Licensed Product.

         (f)      The Company shall pay to MAYO a royalty fee of [***] within
                  thirty (30) days of Company receiving FDA approval of each
                  Licensed Product after the first stent Licensed Product.

         (g)      The Company shall pay to MAYO running royalties of [***] of
                  Net Sales for cumulative Net Sales which are less than [***].
                  For the Company's cumulative Net Sales greater than [***] but
                  less than [***], the running royalties due to MAYO from the
                  Company shall be [***] of Net Sales. For the Company's
                  cumulative Net Sales greater than [***], the running royalties
                  due to MAYO from the Company shall be [***] of Net Sales.

         (h)      In the event the Company has granted sublicenses under this
                  contract, the Company shall pay to MAYO [***] of
                  any and all Sublicense Revenues; provided, however, that for
                  Licensed Products that are stent products MAYO shall receive
                  an amount equal to the greater of: (i) [***] of Sublicense
                  Revenues; or (ii) [***] of the amount that MAYO would have
                  received if the sale by the sublicensee had been made by
                  COMPANY and therefore considered "Net Sales" rather than
                  "Sublicense Revenues."

         (i)      No royalties shall be payable on Licensed Product sales
                  between the Company and any Affiliate of the Company, in which
                  event the royalty shall be based upon the Net Sales of the
                  Company's Affiliate.

         (j)      No multiple royalties shall be due and payable because any
                  Licensed Product is covered by more than one patent that is
                  within the definition of Licensed Rights.

         (k)      MAYO agrees that no royalties shall be due for the use of the
                  Licensed Products for research and commercial development
                  purposes by the Company and its Affiliates or for use by third
                  parties providing research and development activities on
                  behalf of the Company; in seeking governmental and
                  professional approvals, certifications or endorsements; or for
                  training purposes, except where the Company or its Affiliate
                  receives revenues for the sale of the Licensed Products to the
                  organization using the device for such stated purposes.

         (l)      To the extent that the Company obtains, subsequent to the
                  execution of this contract, licenses to third party patents or
                  other intellectual property that are necessary to make, use,
                  import or sell Licensed Products, the Company may deduct from
                  the royalties due to MAYO fifty percent (50%) of the royalties
                  due on such third party patents or intellectual property up to
                  an amount equal to fifty percent (50%) of royalties due
                  hereunder.

         (m)      For purposes of calculating royalties for a Combination
                  Product one of the following methods will be used to determine
                  the appropriate "Net Sales" to which to apply the applicable
                  royalty rate:

                  1.       By multiplying the net sales of the Combination
                           Product during the applicable royalty accounting
                           period ("accounting period") by a fraction, the
                           numerator of which is the aggregate gross selling
                           price of the Licensed Product contained in the
                           Combination Product if sold separately, and the
                           denominator of which is the sum of the gross selling
                           price of the Licensed Product, and the Unlicensed
                           Component(s) contained in the Combination Product if
                           sold separately; or

                  2.       In the event that no such separate sales are made of
                           the Licensed Product or the

                                       5
<PAGE>   6

                           Unlicensed Component(s) during the applicable
                           accounting period, Net Sales for purposes of
                           determining royalties payable hereunder shall be
                           calculated by multiplying the Net Sales of the
                           Combination Product by a fraction, the numerator of
                           which is the fair market value of the Licensed
                           Product and the denominator of which is the sum of
                           the fair market value of the Licensed Product and the
                           Unlicensed Component(s) contained in the Combination
                           Product.

4.03 TAXES. The COMPANY is responsible for all taxes (other than net income
taxes), duties, import deposits, assessments, and other governmental charges,
however designated, which are now or hereafter will be imposed by any authority
in or for the Territory: (a) by reason of the performance by MAYO of its
obligations under this contract, or the payment of any amounts by the COMPANY to
MAYO under this contract; (b) based on the Licensed Products or use of the
Licensed Products; or (c) which relate to the import of the Licensed Products
into the Territory.

4.04 NO DEDUCTIONS. All payments to be made by the COMPANY to MAYO under this
contract represent net amounts MAYO is entitled to receive, and shall not be
subject to any deductions or offsets for any reason whatsoever. If such payments
become subject to taxes, duties, assessments, or fees of any kind levied in the
Territory, such payments from the COMPANY shall be increased to the extent that
MAYO actually receives the net amounts due under this contract.

4.05  U.S. CURRENCY.  All payments to MAYO under this contract shall be made by
draft drawn on a United States bank, and payable in United States dollars.

                     ARTICLE 5.00 - ACCOUNTING AND REPORTS.

5.01 PAYMENT. The COMPANY will deliver to MAYO on or before the following dates:
1 February, 1 May, 1 August, and 1 November, a written report stating Net Sales
and Sublicense Revenues during the preceding License Quarter on which royalties
are to be based, or stating the status of development of the Licensed Rights,
and of preparations to market the Licensed Products if marketing has not yet
begun. Each such report shall be accompanied by the royalty payment due for such
License Quarter, as provided in Section 4.02.

5.02 ACCOUNTING. The COMPANY shall keep complete, true, and accurate books of
accounts and records for the purpose of showing the derivation of all royalties
payable to MAYO under this contract. Such books and records shall be kept at the
COMPANY's principal place of business for at least three (3) years after the end
of the License Year to which they pertain, and shall be open at all reasonable
times for inspection by a representative of MAYO for verification of royalty
statements or compliance with other aspects of this contract. The MAYO
representative shall treat as confidential all relevant matters and shall be a
person or firm reasonably acceptable to the COMPANY. MAYO may specify that its
representative shall be an independent Certified Public Accountant. If any
inspection indicates the royalty payments due MAYO have been under calculated by
the COMPANY by ten (10) or more percent for any License Year, then the COMPANY
shall promptly reimburse MAYO for all reasonable costs incurred in connection
with the inspection. Failure to reimburse MAYO in such an instance, upon MAYO's
demand, is a Material Breach of this contract, unless the COMPANY, in good
faith, disputes the results of the inspections.

                                       6
<PAGE>   7

                 ARTICLE 6.00 - WARRANTIES AND INDEMNIFICATION.

6.01 USE OF NAME AND LOGO. The COMPANY shall be entitled to use publicly for
publicity, promotion, or otherwise, the logos, names, trade names, service
marks, and trademarks listed and described on Exhibit B attached hereto, or any
simulation abbreviation or adaptation of the same or similar logos, marks and
names as MAYO may approve, in writing, which consent shall not be unreasonably
withheld. Except in connection with the permitted uses described above, the
COMPANY shall not (i) register nor attempt to register in any jurisdiction in
the world any trademark or service mark that includes the word "MAYO" in any
language or alphabet, or that includes any word or symbol confusingly similar to
any of MAYO's marks; nor (ii) use any such word or mark in commerce anywhere in
the world without MAYO's prior, express, written consent. Violation of this
Section 6.01 is a Material Breach of this contract, entitling MAYO to
appropriate equitable or legal relief.

6.02  PATENT MATTERS.  MAYO warrants and represents that:

         (a)      It owns or has a license to the Licensed Rights and Licensed
                  Know-How and that it has not made any commitments to others
                  regarding the Licensed Rights and/or Licensed Know-How in the
                  Field of Use that would conflict with the rights granted to
                  the Company hereunder.

         (b)      It has not received written notice from any third party that
                  any composition, process or use claimed by the Licensed Rights
                  infringes an issued patent of such third party.

         (c)      It has no actual knowledge of any current action conducted by
                  a third party which is or would constitute an infringement of
                  the Licensed Rights in the Field of Use.

         (d)      To its knowledge the Licensed Rights permit the manufacture,
                  use, sale and importation of Licensed Products without
                  infringement upon registered rights of any third party within
                  the United States of America.

         (e)      It has reviewed its intellectual property portfolio and
                  believes that there are no other patents or patent
                  applications owned by MAYO or licensed to MAYO with the right
                  to grant sublicenses which would be infringed in the practice
                  of the Licensed Rights in the Field of Use in the Territory or
                  in the manufacture, use, sale and importation of Licensed
                  Products.

         (f)      The rights in and to the Licensed Rights and Licensed Know-How
                  granted to the Company under this contract are free and clear
                  of liens, claims and encumbrances of any third parties
                  claiming by, through or under MAYO.

Except as expressly provided in this contract, nothing shall be construed as:

(a)      a warranty or representation by MAYO as to the validity or scope of any
         patents contained in the Licensed Rights;

(b)      an obligation to bring or to prosecute actions against third parties
         for infringement of patent; or

(c)      conferring by implication, estoppel, or otherwise any patents of MAYO.

6.03 WARRANTIES. MAYO HAS NOT MADE AND PRESENTLY MAKES NO PROMISES, GUARANTEES,
REPRESENTATIONS OR WARRANTIES OF ANY NATURE, DIRECTLY OR INDIRECTLY, EXPRESS OR
IMPLIED, REGARDING THE MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE,
SUITABILITY, DURABILITY, CONDITION, QUALITY, OR ANY OTHER CHARACTERISTIC OF THE
LICENSED PRODUCTS. THE COMPANY TAKES THE LICENSED PRODUCTS "AS IS," "WITH ALL
FAULTS," AND "WITH ALL DEFECTS," AND,

                                       7
<PAGE>   8

EXCEPT AS OTHERWISE SPECIFICALLY PROVIDED HEREIN, EXPRESSLY WAIVES ALL RIGHTS TO
MAKE ANY CLAIM WHATSOEVER AGAINST MAYO FOR MISREPRESENTATION OR FOR BREACH OF
PROMISE, GUARANTEE, OR WARRANTY OF ANY KIND RELATING TO THE LICENSED PRODUCTS.

6.04 INDEMNIFICATION. The COMPANY shall defend, indemnify, and hold harmless
MAYO and MAYO's Affiliates from all third party liability, demands, damages,
expenses, losses, fees (including attorneys' fees) and settlements, for death,
personal injury, illness, or tangible personal property damage arising out of:

(a)      use by the COMPANY of inventions or information furnished under this
         contract; and

(b)      use, sale, or other disposition of Licensed Products by the COMPANY or
         its transferees.

As used in Sections 6.04 (a) and (b), and 6.05, MAYO and its Affiliates include
the trustees, officers, agents, and employees of MAYO and its Affiliates. During
the term of this contract in which it sells or uses or otherwise distributes
Licensed Products for their intended uses, the COMPANY shall carry
occurrence-based product liability insurance with policy limits of at least Two
Million ($2,000,000). In addition, such policy shall name MAYO as an additional
insured.

6.05 WAIVER OF SUBROGATION. The COMPANY expressly waives any right of
subrogation that it may have against MAYO resulting from any claim, demand,
liability, judgment, settlement, costs, fees (including attorneys' fees), and
expenses for which the COMPANY has agreed to indemnify MAYO and its Affiliates
or hold MAYO and its Affiliates harmless under Section 6.04 of this contract.

6.06 ADDITIONAL WAIVERS. THE COMPANY AGREES THAT MAYO SHALL NOT BE LIABLE FOR
ANY LOSS OR DAMAGE CAUSED BY DELAY IN FURNISHING PRODUCTS OR SERVICES, OR ANY
OTHER PERFORMANCE OF PHYSICAL DELIVERY OF GOODS OR SERVICES UNDER THIS CONTRACT,
UNLESS RESULTING FROM MAYO'S NEGLIGENCE OR WILFUL AND WANTON MISCONDUCT. IN NO
EVENT SHALL MAYO'S LIABILITY OF ANY KIND INCLUDE ANY SPECIAL, INDIRECT,
INCIDENTAL, OR CONSEQUENTIAL LOSSES OR DAMAGES, EVEN IF MAYO HAS BEEN ADVISED OF
THE POSSIBILITY OF SUCH DAMAGES. IN NO CASE SHALL MAYO'S LIABILITY FOR DAMAGES
OF ANY TYPE EXCEED THE TOTAL PAYMENTS THAT HAVE BEEN OR WILL BE MADE TO MAYO BY
THE COMPANY UNDER THIS CONTRACT.

                      ARTICLE 7.00 - TERM AND TERMINATION.

7.01 TERM. The term of this contract is for the longer of 20 years, or for the
life of the last of any Licensed Rights that may issue.

7.02 TERMINATION FOR MATERIAL BREACH. If the COMPANY defaults in the payment of
any royalty, fees, payment, or in the making of any report; or makes a false
report; or commits another Material Breach of this contract, MAYO may, at its
sole option, terminate this contract upon written notice to the COMPANY,
termination being effective on the twentieth (20th) business day after the
giving of notice to the COMPANY, unless such default or other Material Breach is
first cured to MAYO's reasonable satisfaction.

                                       8
<PAGE>   9

7.03 CHALLENGE BY OR INSOLVENCY OF COMPANY. MAYO may terminate this contract
immediately upon written notice to the COMPANY if the COMPANY ceases conducting
business in the normal course, becomes insolvent or bankrupt, makes a general
assignment for the benefit of creditors, admits in writing its inability to pay
its debts as they are due, permits the appointment of a receiver for its
business or assets, or avails itself of or becomes subject to any proceeding
under any statute of any governing authority relating to insolvency or the
protection of rights of creditors.

7.04 INFRINGEMENT OF THIRD PARTY RIGHTS. If the COMPANY discontinues
manufacturing, use, sale, importation, or marketing the Licensed Products or the
sublicensing of such rights because of infringement of the rights of a third
party, then this contract may be terminated upon written notice from the
COMPANY, accompanied by written proof of the infringement claims.

7.05  SURVIVAL.  The following obligations survive the Termination of this
contract:

(a)      the COMPANY's obligation to supply reports covering the time period up
         to the date of Termination;

(b)      MAYO's right to receive payments, fees, and royalties (including
         minimum royalties) accrued or accruable from payment at the time of any
         Termination;

(c)      the COMPANY's obligation to maintain records, and MAYO's right to have
         those records inspected;

(d)      any cause of action or claim of a party, accrued or to accrue, because
         of any action, misrepresentation or omission by the other party;

(e)      the COMPANY's obligations stated in Sections 3.04 and 6.04 of this
         contract; and

(f)      the COMPANY's obligation to return all materials given to it by MAYO.

7.06  SURVIVAL OF SUBLICENSES. Any sublicense agreement which MAYO has
confirmed as provided in Section 3.05 above shall survive any such termination
provided the sublicensee cures any of its defaults under the sublicense, agrees
to substitute MAYO as the sublicensor for all future payments and agrees that
MAYO has all of the rights of the COMPANY under the sublicense.

                          ARTICLE 8.00 - BEST EFFORTS.

8.01 REPRESENTATIONS OF THE COMPANY. The COMPANY has represented to MAYO, to
induce MAYO to enter into this contract, that the COMPANY will commit itself to
a thorough, vigorous, and diligent program of obtaining the necessary regulatory
approval for the use of the Licensed Products and thereafter marketing the
Licensed Products.

8.02 REASONABLE EFFORTS. If at any time during the term of this contract the
COMPANY is not exercising, or is then presently unable to exercise, reasonable
efforts in the development, production, quality control, service, manufacture,
marketing, or sales of the Licensed Products, and fails to cure such defects
within sixty (60) days following receipt of written notice of the same, then
MAYO may terminate this contract immediately upon written notice to the COMPANY.
So long as the COMPANY has received not less than $5,000,000 in accordance with
a funding schedule set forth in a development plan as agreed to by the parties,
it shall be deemed to be using reasonable efforts so required under this Article
8.

                                       9
<PAGE>   10

8.03 ABANDONMENT OF EFFORTS. In the event that COMPANY ceases to make reasonable
business efforts for a period of 18 consecutive months to develop a product that
is covered by at least one claim of a patent or patent application listed on
Exhibit A and thereafter fails to initiate appropriate remedial action within 30
days after receiving written notice from MAYO of such deficiency, that patent or
patent application shall be deemed deleted from Exhibit A and COMPANY shall no
longer have any rights with respect to such patent or patent application or any
patents issuing on such application. In the event that COMPANY decides to
abandon reasonable commercial development efforts of any of the Licensed Rights,
the COMPANY shall promptly give to MAYO written notice of abandonment and that
Licensed Right shall be deemed deleted from Exhibit A and COMPANY shall no
longer have any rights with respect to any such Licensed Right.

                             ARTICLE 9.00 - PATENTS.

9.01 PATENT NUMBERS. The COMPANY shall, if practical, mark all Licensed Products
units sold in the United States with any applicable United States patent
numbers, and all Licensed Products units sold in countries other than the United
States with any applicable patent numbers of the country of sale. All Licensed
Products units shipped to or sold in other countries in the Territory shall be
marked in such a manner as to conform with the patent laws and other laws of the
country of manufacture or sale.

9.02 INFRINGEMENT BY THIRD PARTY. The COMPANY shall promptly inform MAYO of any
suspected infringement of any licensed patent rights by a third party, and MAYO
and the COMPANY shall have the right to institute an action for infringement of
the licensed patent rights against such third party consistent with the
following:

(a)      If MAYO and the COMPANY agree to institute suit jointly, then the suit
         shall be brought in the names of both parties. The costs of litigation,
         including attorneys' fees, shall be borne equally, and recoveries, if
         any, whether by judgment, award, decree, arbitration, or settlement,
         shall be shared equally. The COMPANY shall exercise control over such
         action, provided, however, that MAYO may, if it so desires, be
         represented by counsel of its own selection, and at its own expense.

(b)      In the absence of an agreement to institute a suit jointly, the COMPANY
         may institute suit and, at its option, join MAYO as a plaintiff. The
         COMPANY shall bear the entire cost of such litigation, including
         attorneys' fees, and shall be entitled to retain from the amount of any
         recovery by way of judgment, award, decree, arbitration, or settlement
         all costs and expenses associated with the enforcement action and the
         remainder shall be considered Net Sales. MAYO shall cooperate
         reasonably with the COMPANY, except financially, in such litigation.

(c)      In the absence of an agreement to institute a suit jointly, and if the
         COMPANY determines not to institute a suit, as provided in paragraph
         (b) of this Section 9.02, then MAYO may institute suit and, at its
         option, join the COMPANY as a plaintiff. MAYO shall bear the entire
         cost of such litigation, including attorneys' fees, and shall be
         entitled to retain the entire amount of any recovery by way of
         judgment, award, decree, arbitration, or settlement. The COMPANY shall
         cooperate reasonably with MAYO, except financially, in such litigation.

(d)      If either party institutes a suit under this Section and then decides
         to abandon the suit, it shall first provide timely written notice to
         the other party of its intention to abandon the suit, and the other
         party, if it wishes, may continue prosecution of such suit, provided,
         however, that the sharing of expenses and of any recovery in such suit
         shall be agreed-upon separately by the parties.

                                       10
<PAGE>   11

9.03 PATENTS. The COMPANY shall pursue patent coverage and maintain patents for
the Licensed Products at its own expense. Any patents resulting from the
Licensed Rights or based upon the Licensed Products arising out of research
conducted by MAYO and sponsored by the COMPANY shall be applied for on behalf of
MAYO, and all rights shall be assigned to MAYO except that all such patents
shall be included within the definition of Licensed Rights and therefore
included in the license granted to the COMPANY hereunder. In the event the
COMPANY elects to cease the prosecution of any Licensed Rights, COMPANY shall
provide MAYO, within thirty days following the execution of this contract, a
list of jurisdictions in which COMPANY intends to prosecute and maintain the
patents listed on Exhibit A. If COMPANY elects not to pursue or maintain such
patents in any such jurisdiction, it shall notify MAYO not less than sixty days
before action or inaction is required within that jurisdiction. Upon giving such
notice, COMPANY shall have no further obligations or rights with respect to such
patent or patent application within that jurisdiction.

                       ARTICLE 10.00 - GENERAL PROVISIONS.

10.01 ASSIGNMENT AND SUBCONTRACT. Except as otherwise provided herein, the
COMPANY is strictly prohibited from assigning or subcontracting any of its
obligations or rights under this contract without MAYO's prior, express, written
consent, which consent may be withheld in MAYO's sole discretion. Any other
attempted assignment or subcontract is void. This contract is personal to the
COMPANY. The foregoing notwithstanding, this Section 10.01 does not limit
COMPANY'S exclusive license granted in Section 3.01 nor the Company's related
right to sublicense granted in Section 3.05.

10.02 WAIVER. No part of this contract may be waived except by the further
written agreement of the parties. Forbearance in any form from demanding the
performance of a duty owed under this contract is not a waiver of that duty.
Until complete performance of a duty owed under this contract is accomplished,
the party to which that duty is owed may invoke any remedy under this contract
or under law, despite its past forbearance in demanding performance of that
duty.

10.03 GOVERNING LAW AND JURISDICTION. This contract is made and performed in
Minnesota. It is governed by Minnesota law, but specifically not including
Article 2 of the Uniform Commercial Code as enacted in Minnesota. This is not a
contract for the sale of goods. In addition, no Minnesota conflicts-of-law or
choice-of-laws provisions apply to this contract. To the extent the substantive
and procedural law of the United States would apply to this contract, it
supersedes the application of Minnesota law. The parties agree that all disputes
between them concerning this contract, whether arising before or after
Termination, will be settled only according to the arbitration process described
in Exhibit C, attached to and incorporated into this contract, and not through
any action at law or in equity, except as otherwise permitted under Exhibit C.

10.04 HEADINGS. The headings of articles and sections used in this document are
for convenience of reference only, and are not a part of this contract.

10.05 NOTICES. Any notice required to be given under this contract is properly
provided if in writing and either personally delivered, or sent by express or
certified mail, postage prepaid, to the parties at the following addresses,
unless other addresses are provided consistent with this Section 10.5:

Mayo Foundation for Medical Education and Research
200 First Street SW

                                       11
<PAGE>   12

Rochester, Minnesota 55905-0001
Attn:  Office of Technology Transfer, Mayo Medical Ventures

GMP|Cardiac Care, Inc.
One East Broward Boulevard, Suite 1701
Fort Lauderdale, FL  33301
ATTN:  Michael Salem, Vice President

Unless otherwise expressly specified in this contract, notices sent by mail are
considered effective upon the earlier of: the fifth (5th) day after dispatch (or
the tenth (10th) day after dispatch if dispatched by air mail other than in the
United States) or the day of actual receipt. Notices personally delivered are
considered effective upon the date of delivery. It is the responsibility of the
party giving notice to obtain a receipt for delivery of the notice, if that
party considers such a receipt advisable.

10.06 LIMITATION OF RIGHTS CREATED. This contract is intended only to benefit
the two parties to it. They have no intention to create any interests for any
other party. Specifically, no interests are intended to be created for any
customer, patient, research subjects, or other persons (or their relatives,
heirs, dependents, or personal representatives) by or upon whom the Licensed
Products may be used.

10.07 INDEPENDENT CONTRACTORS. In the performance of their respective duties
under this contract, the parties are independent contractors of each other.
Neither is the agent, employee, or servant of the other. Each is responsible
only for its own conduct.

10.08 ENTIRE CONTRACT. This document states the entire contract between the
parties about its subject matter. All past and contemporaneous discussions,
agreements, proposals, promises, warranties, representations, guarantees,
correspondence, and understandings, whether oral or written, formal or informal,
are entirely superseded by this contract.

10.09 UNENFORCEABLE PROVISION. The unenforceability of any part of this contract
will not affect any other part. This contract will be construed as if the
unenforceable parts had been omitted.

10.10 CHANGES TO CONTRACT. No part of this contract, including this Section
10.10, may be changed except in writing, through another document signed by both
parties.

10.11 CONSTRUCTION. Both parties agree to all of the terms of this contract.
Both parties execute this contract only after reviewing it thoroughly. That one
party or the other may have drafted all or a part of this contract will not
cause this contract to be read more strictly against the drafting party. This
contract, and any changes to it, will be interpreted on the basis that both
parties contributed equally to the drafting of each of its parts.

10.12 NONDISCLOSURE. Neither party shall disclose any of the terms of this
contract without the express, prior, written consent of the other party, or
unless required by law.

       The next page of this contract is the signature page.
       The signature page is followed by Exhibits A, B and C.
       Exhibit C is the end of this contract.

                                       12
<PAGE>   13

This is the signature page for the TECHNOLOGY LICENSE CONTRACT.

MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH:

Signed:
       ----------------------------------------------

Printed Name:
             ----------------------------------------

Title:
      -----------------------------------------------

Date:                   May 26, 2000
      -----------------------------------------------

GMP|CARDIAC CARE, INC.:

Signed:
       ----------------------------------------------

Printed Name:             Bart Chernow, M.D.
              ---------------------------------------

Title:                  President
      -----------------------------------------------

Date:                    May 26, 2000
      -----------------------------------------------

Exhibit A - Licensed Rights
Exhibit B - Permitted Uses of Mayo Name and Logos
Exhibit C - Mandatory Mediation and Binding Arbitration

                                       13
<PAGE>   14

                                    EXHIBIT A

                                 LICENSED RIGHTS

1.       Patent No. 5,895,376 Hemostasis Valve, System and Assembly, issued
         April 20, 1999

2.       Patent Application Multi-Section Stent MMV 98-060, U.S. app.
         09/292,588, filed 4/15/99 (a stent for purposes of Section 4.02)

3.       Patent Application Automatic Manifold for Vascular Catheter MMV 95-111,
         U.S. app. 09/159,008, filed 9/23/98

4.       Patent Application Apparatus for Flushing a Vascular Catheter MMV
         95-109, U.S. app. 09/159,007, filed 9/23/98

5.       Patent Application De-Bubbling Apparatus and Method of Use MMV 95-113,
         U.S. app. 09/159,007, filed 9/23/98

6.       Patent-Application-in-Process: MMV Disclosure by David R. Holmes, Jr.,
         M.D. and Robert S. Schwartz, M.D. regarding "Radiation Therapy,
         Alternative Approaches"

7.       Patent-Application-in-Process: MMV Disclosure by Robert S. Schwartz,
         M.D. and David R. Holmes, Jr., M.D. regarding "Novel Therapy for
         Chronic Total Occlusion" (a stent for purposes of Section 4.02)

8.       MMV Disclosure by David R. Holmes, Jr., M.D. and Robert S. Schwartz,
         M.D. regarding the "Smart Card"

                                       i

<PAGE>   15

                                    EXHIBIT B

                      PERMITTED USES OF MAYO NAME AND LOGOS

MAYO agrees that COMPANY may use its name:

         1.       To publicize and promote the relationship between MAYO and
                  COMPANY and the Licensed Products with the following phrase:
                  "Developed in cooperation with MAYO Clinic";

         2.       In connection with press releases and other publications that
                  have received MAYO's prior approval, which approval shall not
                  be unreasonably withheld and any such request for approval
                  shall be acted on and responded to by MAYO within five
                  business days of the receipt of the request; provided,
                  however, once COMPANY receives MAYO'S approval on a particular
                  use, COMPANY is deemed to have MAYO approval to continue to
                  use the same for other similar purposes; and

         3.       To comply with the disclosure requirements, as reasonably
                  interpreted by COMPANY'S counsel, of all applicable laws and
                  regulations relating to its business, including United States
                  and state securities laws.

                                       ii

<PAGE>   16

                                    EXHIBIT C

                   MANDATORY MEDIATION AND BINDING ARBITRATION

1.       NOTICE OF DISPUTE. Any dispute related to this Agreement between the
parties, including its formation, performance, or termination, which cannot be
resolved by the parties themselves within thirty (30) days of written notice by
one party to the other of the existence of a dispute, may be referred by either
of the parties to mandatory mediation and binding arbitration under the terms of
this Exhibit. The parties intend the mediation/arbitration procedure described
in this Exhibit to substitute in all cases for litigation related to any such
dispute, subject only to Section 7, below, and this agreement to submit all such
disputes to mandatory mediation and binding arbitration is irrevocable.

2.       LIMITATION PERIOD.  No demand for mediation/arbitration may be made
regarding any claim more than one hundred eighty (180) days after written notice
by one party to the other of the existence of a dispute, regardless of any
otherwise applicable statute of limitations.

3.       MEDIATOR/ARBITRATOR. If the parties cannot agree upon a single
mediator/arbitrator within fourteen (14) days after written demand by either of
them for mediation/arbitration, then a single mediator/arbitrator shall be
chosen by the American Arbitration Association office in Minneapolis, Minnesota,
within thirty (30) additional days after the fourteen (14) day period. The
mediator/arbitrator shall be generally experienced in the legal and technical
matters related to the dispute.

4.       MEDIATION. Within thirty (30) days of the appointment of the
mediator/arbitrator, the parties must attend a mediation session at which the
mediator/arbitrator personally shall attempt to guide the parties to a
settlement. Each party may be represented by counsel at the mediation, but each
party must attend through an officer having authority to agree to a settlement
at the mediation. The mediation session shall occur in Minneapolis or in St.
Paul, Minnesota, and shall extend no longer than a single day. Statements or
offers made at the mediation session shall not be admissible in any later
arbitration hearing.

5.       ARBITRATION. If such mediation has not resulted in a mutually-executed
settlement agreement (or withdrawal of claim) within five (5) business days
after the date of mediation, then the parties shall proceed to arbitration as
described below. Such arbitration, which the parties intend to be final and to
substitute for litigation, shall occur in Minneapolis or in St. Paul, Minnesota,
and the arbitration results may be entered as a final judgment in any court with
jurisdiction. The decision of the arbitrator shall be final and binding upon the
parties both as to law and fact.

(a)      Initial Disclosures. Within twenty-one (21) days after the date of
mediation, the parties shall exchange written disclosures listing with
reasonable specificity: (i) all exhibits expected to be used by the party at
arbitration, and complete copies of such exhibits, (ii) all witnesses expected
to be called by the party at arbitration, and (iii) the substance of the
testimony of each witness. Copies of such disclosures shall be sent to the
arbitrator. No exhibit or witness may be called if the same does not appear on
such disclosure, and no witness may testify as to matters not described in such
disclosure, except for rebuttal testimony as may be permitted by the arbitrator.

(b)      Discovery Period. Within fourteen (14) days after exchange of the
disclosure notices, the parties shall make specific discovery requests to the
arbitrator, and within an additional fourteen (14) days the arbitrator shall
issue to both parties a joint discovery order. The discovery period preceding
the arbitration hearing shall not exceed sixty (60) days from the issuance of
the discovery order by the arbitrator.

                                      iii

<PAGE>   17

(c)      Scope of Discovery. Discovery shall be limited to that ordered by the
arbitrator as being reasonable and necessary, and in no case shall exceed the
deposition of two (2) witnesses for each party, and/or the exchange of more than
a total of twenty-five (25) specific and non-compound interrogatories by each
party, and/or two specific requests by each party for the production of
documents considered by the arbitrator to be reasonably relevant and not unduly
burdensome.

(d)      Hearing. The arbitration hearing, which shall be confidential to the
parties and not open to the public, shall not exceed two (2) separate days, and
shall be completed within thirty (30) days of the close of discovery. The
arbitrator may admit any testimony or other evidence which the arbitrator
decides is reasonably relevant to the issues of the arbitration, but excluding
statements or offers made by either party at the mediation session.

(e)      Final Decision. The arbitrator shall issue a final written decision no
later than sixty (60) days following the end of the arbitration hearing, stating
findings as to law and fact. The decision shall be confidential to the parties.
The arbitrator shall be limited to determining and ordering the payment of
actual and direct damages if any, and may order the payment of indirect,
special, incidental, or consequential damages only where bad faith has been
shown and/or to the extent required to fulfill any obligations under Article 7
of the Agreement. The arbitrator shall not order the payment of punitive or
exemplary damages in any case.

6.       COSTS AND FEES. Both parties shall be responsible for their own costs
and fees (including attorney's fees), and shall divide common costs and fees
equally; however, if the arbitrator specifically finds bad faith on the part of
either party, then the arbitrator may order a different division of costs and
fees.

7.       EQUITABLE RELIEF. Nothing in this Exhibit prohibits either party from
seeking equitable relief to protect its rights to the extent that irreparable
harm may occur and damages would not be a sufficient remedy, except that neither
party shall seek to enjoin mediation/arbitration as described in this Exhibit.

(a)      Specific Performance. Among the equitable remedies that a party may
seek under this part 7, either party may petition a court for specific
performance of the terms of this Exhibit, including following the failure of
either party without good cause to adhere to the time limits set out in this
Exhibit. A party securing an order for specific performance under this part 7(a)
is entitled to recover costs and reasonable attorneys' fees in connection with
such petition for specific performance and any related hearings.

8.       GOVERNING RULES AND LAW.  To the extent not inconsistent with the terms
of this Exhibit, the mediation and arbitration are governed by the rules of the
American Arbitration Association, the Minnesota Arbitration Act, and the Federal
Arbitration Act (9 U.S.C s. 1 et seq.).

                                       iv<PAGE>   1
                                                                   EXHIBIT 10.18

                             SHAREHOLDERS' AGREEMENT

<PAGE>   2

                             SHAREHOLDERS' AGREEMENT

         THIS SHAREHOLDERS' AGREEMENT (this "Agreement") dated as of July 27th,
2000, is entered into by and among GMP|Wireless Medicine, Inc., a Delaware
corporation (the "Company"), GMP|Companies, Inc., a Delaware corporation
("GMP"), and Motorola, Inc., a Delaware corporation ("Motorola")(GMP and
Motorola are hereinafter sometimes referred to individually as a "Shareholder"
and collectively as the "Shareholders"), as amended from time to time to add
such other person(s) who may hereafter become a party to this Agreement.

                                    RECITALS

         A.       As provided for in the Amended and Restated License and
Cross-License Agreement dated this even date between the Company and Motorola
(the "License Agreement"), the Company will issue to Motorola an aggregate of
One Million Five Hundred Thousand (1,500,000) shares of the Company's Class B
Common Stock, par value $0.001 per share (the "Class B Common Stock"), pursuant
to the terms and conditions of the Stock Acquisition Agreement of even date
herewith and as a part of the transactions between the Company and Motorola
described in the License Agreement.

         B.       As provided for in the License Agreement, the Company will
issue and sell to GMP an aggregate of Eight Million Five Hundred Thousand
(8,500,000) shares of the Company's Class A Common Stock, par value $0.001 per
share (the "Class A Common Stock" and, together with the Class B Common Stock,
the "Common Stock") pursuant to the terms and conditions of the Stock Purchase
Agreement between the Company and GMP of even date herewith.

         C.       As provided in the License Agreement, Motorola will also be
granted certain options to purchase shares of common stock of GMP from GMP and
an option to purchase certain shares of the Class A Common Stock from GMP.

         D.       The Shareholders and the Company agree to provide herein for
the options described above and agree that it is in their mutual best interest
and in the best interest of the Company to provide certain rights, obligations
and restrictions with respect to the Common Stock now or hereafter owned by the
Shareholders and any other capital stock of the Company or securities
convertible into, exchangeable for or having rights to purchase capital stock of
the Company (such capital stock, securities and Common Stock are hereinafter
referred to collectively as "Stock").

                                    AGREEMENT

         NOW, THEREFORE, in consideration of the premises, the mutual covenants
and agreements herein contained, and other valuable consideration, the receipt,
adequacy and sufficiency whereof are hereby acknowledged, the parties hereto,
intending to be legally bound, do hereby covenant and agree as follows:

                                       1
<PAGE>   3

                                    ARTICLE I

                Restrictions on Transfer/Rights of First Refusal

         1.1      Restrictions on Transfer. Except as otherwise provided by
Section 1.6, no Shareholder (including transferees of Shareholders) shall
transfer any Stock, or any interest therein, whether by operation of law or
otherwise, except in accordance with all of the provisions of this Agreement. As
used in this Agreement, the term "transfer" shall include any sale, pledge,
gift, assignment or other disposition of shares of Stock.

         1.2      First Offer. If a Shareholder (the "Selling Shareholder")
desires to transfer any or all of such Shareholder's Stock (the "Offered
Stock"), such Shareholder shall first give written notice (a "Transfer Notice")
thereof to the Company and the other Shareholders, identifying the proposed
transferee, the number of shares sought to be transferred, the proposed purchase
price (the "Offered Price"), if applicable, the terms of the proposed
transaction including the proposed transaction date and a copy of any written
offer or other writing setting forth the terms and conditions of the proposed
transaction. Such Transfer Notice shall constitute an irrevocable offer by the
Selling Shareholder to sell all of the Offered Stock to the other Shareholders
at the Offered Price and upon the same terms and conditions as the Selling
Shareholder is willing to sell the Offered Stock to the proposed transferee;
provided, however, that without the prior written consent of the other
Shareholders (which consent shall not be unreasonably withheld), all transfers
pursuant to this Article I shall be solely for cash. Once given, a Transfer
Notice may not be modified or amended except with the written consent of the
Company and the Shareholders (or their Permitted Transferees (as defined in
Section 1.6 below)) holding at least two-thirds of the Common Stock of the
Company. Within the twenty (20) day period following the giving of the Transfer
Notice (the "First Offer Period"), the other Shareholders may elect, by giving
written notice of such election to the Selling Shareholder and the Company, to
purchase all but not less than all of the Offered Stock. If more than one of the
Shareholders makes such election, each such electing Shareholder shall purchase
its pro rata share based upon the number of shares of Common Stock held by it at
the time of the election. Any modification or amendment of a Transfer Notice
will be deemed a new Transfer Notice with respect to the proposed transfer and
will restart the First Offer Period.

         1.3      Second Offer. If the other Shareholders do not elect to
purchase all of the Offered Stock within the First Offer Period, the Offered
Stock shall then be offered by the Selling Shareholder to the Company for a
period of ten (10) days from the end of the First Offer Period (the "Second
Offer Period"). The Company shall have the right to purchase all, but not less
than all, of the Offered Stock upon the same terms and conditions as set forth
in the Transfer Notice.

         1.4      If the other Shareholders and the Company do not elect to
purchase all (but not less than all) of the Offered Stock, the Selling
Shareholder shall be free to dispose of all of the Offered Stock within ninety
(90) days of the end of the Second Offer Period to the original proposed
transferee, at a price not lower than the Offered Price, and upon the terms
stipulated in the Transfer Notice in all material respects; provided, however,
that any such sale shall be subject to participation by the Shareholders
pursuant to the provisions of Section 2.1. However, as a condition to the
effectiveness of such transfer, said transferee shall thereupon become a party
to

                                       2
<PAGE>   4

this Agreement as a Shareholder and, pursuant to Section 6.13, shall confirm
such fact by executing a counterpart of this Agreement. If such Offered Stock is
not so disposed of by the Selling Shareholder within such ninety (90) day
period, the Selling Shareholder shall continue to hold such Stock subject to all
of the terms and conditions of this Agreement and may not sell the Stock without
again complying with all of the provisions hereof. Any transferee of Offered
Stock as to which the right of first refusal set forth in this Article I has not
been exercised shall be referred to herein as follows: (i) if the Offered Stock
was transferred by GMP, a "GMP Transferee," and (ii) if the Offered Stock was
transferred by Motorola, a "Motorola Transferee."

         1.5      Right of First Refusal. Subject to Section 5.2 and the last
clause of this sentence, the Shareholders are hereby given a right of first
refusal by the Company to purchase their respective pro rata portion of any
additional stock issued by the Company; provided, however, that the right of
first refusal granted in this Section 1.5 shall not apply to the issuance by the
Company of up to an aggregate of 500,000 shares of Common Stock (or options to
purchase such shares of Common Stock) (such number being subject to equitable
adjustment as provided by Section 6.10 hereof), issuable pursuant to any stock
option plan of the Company approved by the Board of Directors of the Company.

         1.6      Certain Transfers Not Prohibited. Except as otherwise
expressly provided herein, the restrictions on dispositions of Stock contained
in this Agreement shall not be construed to prohibit the following transfers of
Stock ("Permitted Transfers"):

                  (a)      an involuntary transfer by operation of law;

                  (b)      transfers between Shareholders or by a Shareholder to
                           a subsidiary or parent of such Shareholder or to an
                           "affiliate" of such Shareholder (as such term is
                           defined in Rule 501(b) under the Securities Act of
                           1933, as amended (the "Securities Act");

                  (c)      any transfer of Stock in accordance with Section 2.2
                           of this Agreement; and

                  (d)      any transfer of Stock as part of a firm commitment
                           underwritten public offering of the Company's Common
                           Stock underwritten by a nationally recognized
                           full-service investment bank (a "Qualified Public
                           Offering").

         Any and all Stock in the hands of any transferee pursuant to
subsections (a) and (b) of this Section 1.6 (each a "Permitted Transferee")
shall remain subject to this Agreement. Permitted Transferees under subsections
(a) and (b) of this Section 1.6 shall be deemed to be Shareholders for all
purposes of this Agreement as if they had executed and delivered this Agreement.
The rights to purchase Stock under Article I of this Agreement belong to the
Company and the Shareholders and are not transferable except that any
transferees of Stock under Section 1.6(b), with respect to the shares so
transferred, and any transferee of any Shareholder of not fewer than 500,000
shares of Stock (such number being subject to equitable adjustment as provided
by Section 6.10 hereof) shall also maintain the right to purchase pursuant to
this Article I.

                                       3
<PAGE>   5

         1.7      Payment for Stock. All payments hereunder shall be made in
cash, by wire transfer of immediately available funds. To the extent that the
proposed consideration to be paid by any proposed transferee as described in a
Transfer Notice pursuant to Section 1.2 consists of property other than cash,
and the Company and the other Shareholders provide the requisite written consent
with respect to such non-cash consideration, the purchase price under Sections
1.2 and 1.3 of this Agreement shall be the fair market value of such non-cash
consideration.

         1.8      Delivery of Stock and Documents. Upon the closing of a sale as
herein provided, the Selling Shareholder shall deliver to each purchaser in
exchange for payment of the purchase price: (a) the certificates representing
the Offered Stock purchased by such purchaser, endorsed for transfer and bearing
any necessary documentary stamps, and (b) such assignments, certificates of
authority, tax releases, consents to transfer, instruments and evidence of title
of the Selling Shareholder, and of its compliance with applicable state and
federal laws, as may be reasonably required by counsel for each such purchaser.

                                   ARTICLE II

                                 Co-Sale Rights

         2.1      Tag Along Rights. (a) In the event any Selling Shareholder or
any Permitted Transferee of a Shareholder proposes to sell its Stock and the
Shareholders and the Company have not elected to purchase such Stock in
accordance with Section 1.2 or in a transaction which is not otherwise exempt
under Section 1.6, the Selling Shareholder shall have the right to sell to the
proposed transferee upon the terms and conditions set forth in the Transfer
Notice, subject to the right of the other Shareholders to participate in such
sale in accordance with this Section 2.1. Any Shareholder may elect to
participate in the contemplated transfer by delivering written notice to the
Selling Shareholder within five (5) days after the expiration of the Second
Offer Period. If any other Shareholders have elected to participate in such
transfer, the Selling Shareholder and such other Shareholders shall be entitled
to sell in the contemplated transfer, at the same price and on the same terms, a
number of shares of Stock equal to the product of (i) the quotient determined by
dividing the percentage of Stock owned by such Shareholder by the aggregate
percentage of Stock owned by all Shareholders participating in such sale and
(ii) the number of shares of Stock to be sold in the contemplated transfer.

         For example, if the Transfer Notice contemplated a sale of 70,000
shares of Stock by the Selling Shareholder, and if the Selling Shareholder at
such time owned 60% of all of the Stock and if one other Shareholder elects to
participate and owns 20% of all of the Stock, the Selling Shareholder would be
entitled to sell 52,500 shares of stock (60% / 80% x 70,000 shares of Stock) and
the other Shareholder would be entitled to sell 17,500 shares of Stock (20% /
80% x 70,000 shares of Stock).

         (b)      Each Shareholder who elects to participate in a transfer
pursuant to this Article II shall effect its participation by promptly
delivering to the Selling Shareholder for delivery to the prospective purchaser
one or more certificates, properly endorsed for transfer, which represent the
Stock that such Shareholder elects to sell.

                                       4
<PAGE>   6

         The stock certificate or certificates that the Shareholder delivers to
the Selling Shareholder pursuant to this section shall be transferred to the
prospective purchaser in consummation of the sale of the Stock pursuant to the
terms and conditions specified in the Transfer Notice, and the Selling
Shareholder shall concurrently therewith remit to each Shareholder that portion
of the sale proceeds to which such Shareholder is entitled by reason of its
participation in such sale. To the extent that any prospective purchaser or
purchasers prohibits such assignment or otherwise refuses to purchase shares or
other securities from a Shareholder exercising its right of co-sale hereunder,
the Selling Shareholder shall not sell any Stock to such prospective purchaser
or purchasers unless, simultaneously with such sale, such Selling Shareholder
shall purchase such shares or other securities from each Shareholder electing to
participate under this Section 2.1 on the same terms and conditions specified in
the Transfer Notice.

         The exercise or non-exercise of the rights of the Shareholders
described in this Section 2.1 shall not adversely affect their rights to
participate in subsequent transfers of Stock subject to this section.

         2.2      Obligation to Sell. Subject to the superceding rights in
Section 1.2, in the event the Company or any Shareholder(s) receive(s) a bona
fide written offer to purchase all or substantially all of the assets or all of
the outstanding Stock of the Company, regardless of the form of the proposed
transaction, at the written request of the Company or the selling Shareholder(s)
(the "Selling Party"), as the case may be, each Shareholder shall participate
pro rata in such sale and/or vote all of such Shareholder's shares of Stock in
favor of the transaction, provided that such sale is approved by at least 50.1%
of the outstanding shares of Stock, determined on an a fully diluted basis, held
by the Shareholders (other than the Selling Party). The Company or the Selling
Party, as the case may be, shall give to each Shareholder a notice (an
"Obligation to Sell Notice") containing a description of the material terms of
such proposed transaction including the name and address of the proposed
transferee, the consideration per share offered for such shares by the proposed
transferee, the payment terms and closing date, which shall be a date not less
than sixty (60) days after the giving of the Obligation to Sell Notice, and
including a copy of any written offer, letter of intent, term sheet or contract
of sale. All Shareholders shall be treated equally under this Section 2.2. It
shall be a condition of the obligation to sell under this Section 2.2 that all
facts and circumstances and all material aspects of any transaction under this
Section 2.2 shall be disclosed to all Shareholders.

                                   ARTICLE III

                         Voting and Corporate Governance

         3.1      Voting for Directors. The parties agree to vote their shares
of Stock or consent in writing in the manner necessary to produce the following
effect:

                  (a)      the Board of Directors of the Company shall initially
                           consist of five (5) members;

                                       5
<PAGE>   7

                  (b)      the Company agrees to cause, by action of its Board
                           of Directors, any committee thereof or otherwise, the
                           nomination for election as directors of the Company,
                           one nominee of Motorola, if, and only if, requested
                           by Motorola, and two nominees of GMP (each a
                           "Minority Nominee"); provided, however, that the
                           rights granted in this Section 3.1(b) shall terminate
                           with respect to a Shareholder when such Shareholder
                           or its Permitted Transferees under Section 1.6(b) no
                           longer is the owner of record of at least ten percent
                           (10%) of the issued and outstanding shares of Common
                           Stock on a fully diluted basis;

                  (c)      each Shareholder agrees to take any and all actions,
                           including, but not limited to, voting (i) all shares
                           of Stock held of record by it or of which it is the
                           beneficial owner at the time of such vote or action
                           by written consent and (ii) all shares of Stock as to
                           which such Shareholder at the time of such vote or
                           action by written consent has voting control, in each
                           case, in favor of the election to the Board of
                           Directors of the Minority Nominees nominated in
                           accordance with Section 3.1(b) (each such director
                           hereinafter referred to as a "Minority Director");

                  (d)      each Shareholder agrees to vote or act by written
                           consent with respect to or cause to be voted or acted
                           by written consent (i) all shares of Stock held of
                           record by it or of which it is the beneficial owner
                           at the time of such vote or action by written consent
                           and (ii) all shares of Stock as to which such
                           Shareholder at the time of such vote or action by
                           written consent has voting control, in each case, to
                           remove or cause the removal from office of any
                           Minority Director if the Shareholder that designated
                           such Minority Director requests such removal by
                           notice to the Shareholders;

                  (e)      if at anytime during the term of this Agreement a
                           Minority Director ceases to serve on the Board of
                           Directors of the Company (whether by reason of death,
                           resignation, removal or otherwise), such vacancy
                           shall be filled by the Shareholders of the Company
                           and each Shareholder hereby agrees to vote or act by
                           written consent with respect to or cause to be voted
                           or acted upon by written consent (i) all shares of
                           Stock held of record by it or of which it is the
                           beneficial owner at the time of such vote or action
                           by written consent and (ii) all shares of Stock as to
                           which such Shareholder at the time of such vote or
                           action by written consent has voting control for the
                           vacancy resulting therefrom to be filled by an
                           individual designated by the Shareholder whose
                           Minority Director created such vacancy, in which case
                           such individual, notwithstanding Section 3.1(b),
                           shall be such Shareholders Minority Nominee; and

                  (f)      each Shareholder shall vote its shares of Stock, and
                           shall take all other action necessary including,
                           without limitation, any action necessary to amend the
                           Certificate of Incorporation and the By-Laws, to
                           ensure that the

                                       6
<PAGE>   8

                           Certificate of Incorporation and the By-Laws
                           facilitate and do not at any time conflict with the
                           provisions of this Agreement.

Except as otherwise provided in this Section 3.1, all directors of the Company
shall be elected in the manner prescribed in the By-Laws.

         3.2      Approval by the Board of Directors. The Board shall be
consulted on the Company's entry into or amendment of significant distribution,
licensing or other material agreements or contracts. The approval of (i) at
least 50.1% of the Board of Directors of the Company, and (ii) the approval of
the Minority Directors then in office, shall be required for the following:

                  (a)      changes to the Company's approved stock option, ESOP
                           or comparable compensation plans in which common
                           share equivalents in excess of 5% of outstanding
                           Common Stock of the Company, on a fully diluted
                           basis, are granted or issued;

                  (b)      any merger, consolidation or reorganization of the
                           Company involving any Shareholder or an affiliate
                           thereof; or

                  (c)      any amendment or repeal of any of the provisions of
                           the Company's Certificate of Incorporation.

         3.3      Board Meetings. The Board of Directors shall meet in
accordance with Section 3.5 of the Company's By-Laws. The Company shall
reimburse members of the Board of Directors for the customary and reasonable
expenses of attending the meetings of the Board of Directors.

         3.4      Indemnification. The Company shall not amend the
indemnification provisions of the Company's Certificate of Incorporation or
By-Laws to eliminate or reduce the indemnification provided to all directors and
such provisions as so written shall be deemed to be a contract with each
director regarding his or her indemnification by the Company. The Company may
also enter into separate indemnification agreements with each director.

                                   ARTICLE IV

                                    Dividends

         4.1      General. Subject to Section 4.2, Shareholders shall be
entitled to such dividends as may be declared from time to time by the Board of
Directors of the Company.

         4.2      GMP Dividends. From and after such time as GMP and its
Permitted Transferees under Section 1.6(b) hold fifteen percent (15%) or less of
the issued and outstanding shares of Common Stock on a fully diluted basis,
Motorola shall use its best efforts to cause all directors to propose and vote
at meetings of the Board of Directors or in actions taken by written consent of
the Board of Directors in favor of distributing to GMP and its Permitted
Transferees under Section 1.6(b) quarterly cash distributions of the Company's
net earnings, computed in

                                       7
<PAGE>   9

accordance with generally accepted accounting principles consistently applied,
based on the then outstanding percentage ownership of the Company held by GMP
and its Permitted Transferees under Section 1.6(b).

                                    ARTICLE V

                                Grant of Options

         5.1      Option to Purchase Shares in GMP. GMP hereby grants to
Motorola an option to purchase Fifty Thousand (50,000) shares of the $0.001 par
value common stock of GMP (the "GMP Option"). The exercise price of GMP Option
shall be $18.00 per share, payable in cash at the time of exercise. The GMP
Option shall vest upon completion of an initial public offering by GMP of its
common stock ("IPO") and shall expire five (5) years after the effective date of
that initial public offering ("Expiration Date").

         Exercise of the GMP Option shall be by written notice to GMP (the
"Exercise Notice"), which shall state the election to exercise the GMP Option,
the number of whole shares for which the GMP Option is being exercised and such
other customary representations and agreements as may be reasonably required by
GMP in order to comply with the exemptions from registration under the
Securities Act or other applicable state securities laws and the lock-up
agreements entered into by shareholders of GMP in connection with the IPO. The
Exercise Notice must be signed by Motorola and be delivered in person, by
certified or registered mail, return receipt requested, by confirmed facsimile
transmission, or by such other means as GMP may permit, to the President of GMP,
or other authorized representative of GMP, prior to the Expiration Date,
accompanied by (i) full payment (as evidenced by a check or by wire transfer) of
the aggregate exercise price for the number of shares of GMP stock specified in
the Exercise Notice and (ii) an executed copy of the representations and
agreements, if any, required by GMP as described above. The GMP Option shall be
deemed to be exercised upon receipt by GMP of the Exercise Notice, the aggregate
exercise price, and, if required, the other representations and agreements
required by GMP as described above.

         5.2      Option to Purchase Shares in the Company. As used in this
Section 5.2, Section 5.3 below, Section 6.2 below and Section 6.15 below, the
term "GMP" shall include GMP, any Permitted Transferee of GMP and any GMP
Transferee, and the term "Motorola" shall include Motorola, any Permitted
Transferee of Motorola and any Motorola Transferee. GMP hereby grants to
Motorola an option to purchase from GMP a portion of the shares of the Common
Stock of the Company that GMP owns pursuant to the following schedule and terms
and conditions:

                  a.       Subject to the provisions of Subsection (e) below,
                           beginning on the second (2nd) anniversary after the
                           Company receives its first regulatory approval from
                           both the U.S. Food and Drug Administration and the
                           Federal Communications Commission for the sale or use
                           of a Licensed Product (as defined in the License
                           Agreement) (the "Approval Date") and continuing for a
                           sixty-day period thereafter, Motorola may elect to
                           purchase from GMP an amount of Common Stock of the
                           Company that would increase

                                       8
<PAGE>   10

                           Motorola's equity stake in the Company up to a
                           maximum of fifty percent (50%) of the Company's
                           outstanding Common Stock. For purposes of this
                           subparagraph 5.2(a), outstanding Common Stock shall
                           not include: (i) any percentage of the Common Stock
                           of the Company that is outstanding due to the
                           election of Motorola and/or GMP not to exercise their
                           rights of first refusal as set forth in Section 1.5
                           above; and (ii) the percentage of Common Stock
                           outstanding resulting from any stock option approved
                           by the Board of Directors of the Company.

                  b.       Subject to the provisions of Subsection (e) below, on
                           the earlier to occur of (i) Motorola's receipt of
                           written notice from the Company stating its intention
                           to sell all or substantially all of the assets or
                           capital stock of the Company (such notice to be
                           provided no later than forty-five (45) days prior to
                           the anticipated closing date of such transaction),
                           (ii) Motorola's receipt of written notice from the
                           Company stating its intention to file with the
                           Securities and Exchange Commission a registration
                           statement to initiate a Qualified Public Offering
                           (such notice to be provided no later than forty-five
                           (45) days prior to the initial filing of such
                           registration statement), or (iii) at any time between
                           the fifth (5th) and tenth (10th) anniversaries of the
                           Approval Date, Motorola may elect to purchase from
                           GMP an amount of the outstanding Common Stock of the
                           Company, that would increases Motorola's equity stake
                           in the Company to eighty five percent (85%) of the
                           Company's outstanding Common Stock. For purposes of
                           this subparagraph 5.2(b), outstanding Common Stock
                           shall not include: (i) any percentage of the Common
                           Stock of the Company that is outstanding due to the
                           election of Motorola and/or GMP not to exercise their
                           rights of first refusal as set forth in Section 1.5
                           above; and (ii) the percentage of Common Stock
                           outstanding resulting from any stock option approved
                           by the Board of Directors of the Company.

                  c.       The exercise of the options described in Subsections
                           (a) and (b) above shall be made by Motorola within 15
                           days after receipt of the written notice given by the
                           Company, by giving GMP written notice of such
                           election as provided in Section 6.11 below. Subject
                           to the receipt of any regulatory approvals required
                           in connection with the purchase of the shares, the
                           closing of the purchase of the shares of Common Stock
                           of the Company shall occur on a date and at a place
                           specified by GMP, which date shall be no sooner than
                           twenty (20) days following the date that the Fair
                           Market Value (as defined in Section 5.3 below) is
                           agreed to by the parties or announced by the
                           independent appraisers.

                  d.       In the event that Motorola exercises any of its
                           options described in Subsections (a) or (b) above,
                           Motorola shall, concurrently with the giving of the
                           notice described in Subsection (c) above, offer to
                           purchase a corresponding percentage of Common Stock
                           issued to any person under

                                       9
<PAGE>   11

                           any stock option grant approved by the Board of
                           Directors of the Company pursuant to the same terms
                           described above.

                  e.       The options granted under Subsections (a) and (b)
                           above shall expire upon the consummation of a
                           Qualified Public Offering.

                  f.       The purchase price of the Common Stock of the Company
                           to be purchased by Motorola under Sections 5(a), (b)
                           and (d) above shall be at a price equal to the
                           product of: (i) 105% of the Fair Market Value of the
                           Company (as defined below) at the time of the
                           exercise of such option; and (ii) the ratio that such
                           shares of Common Stock bear to the total outstanding
                           shares of Common Stock of the Company at the time of
                           the exercise of such option.

         5.3      For purpose of this Article V, the "Fair Market Value" of the
Company shall be determined jointly by Motorola and GMP. If such parties are
unable to reach an agreement within thirty (30) days of Motorola providing
written notice that it intends to exercise its option under Section 5(a) or (b),
each party shall, at its own expense and within fifteen (15) days of the end of
such thirty (30) day period, hire an independent qualified valuation
professional of national standing in order to determine the Fair Market Value of
the Company. Such valuation professionals shall: (1) utilize the cost, market
and income approaches in order to determine Fair Market Value of the Company;
(2) be credentialed by the American Society of Appraisers as an "ASA" or be
licensed as a Certified Financial Analyst; (3) conduct the appraisal
simultaneously and in compliance with the Uniform Standards of Professional
Appraisal Practice ("USPAC"); (4) include a control premium or, in the
alternative, not reflect a minority discount, in determining Fair Market Value;
and (5) complete the valuation within seventy-five (75) days of their
appointment (or such other time period as may be mutually agreed to by Motorola
and GMP). Subject to the next paragraph, the Fair Market Value of the Company
shall be determined by taking the average of the two Fair Market Values
determined by each party's appraiser.

         In the event that the difference between these two Fair Market Values
exceeds ten percent (10%) of the highest valuation, a third similarly qualified
independent valuation professional, selected by the two appraisers within
fifteen (15) days of the date the two appraisers submitted their reports, shall
be hired to determine a Fair Market Value within seventy-five (75) days (or such
other time period as may be mutually agreed to by Motorola and GMP), unless GMP
and Motorola otherwise agree to a Fair Market Value. This third valuation
professional shall likewise utilize the cost, market and income approaches and
conduct the appraisal in compliance with USPAC. GMP and Motorola agree to share
equally the costs and expenses incurred by the third valuation professional and
to execute and deliver such engagement letters as are reasonably requested.

         The Fair Market Value of the Company shall be determined by taking the
average of the two closest of the three Fair Market Values.

         5.4      Adjustments for Changes in Capital Structure. In the event of
any stock dividend, stock split, reverse stock split, recapitalization,
combination, reclassification or similar change in

                                       10
<PAGE>   12

the capital structure of GMP, appropriate adjustments shall be made in the
number, class and the exercise price of the shares subject to the option granted
to Motorola in Section 5.1.

                                   ARTICLE VI

                            Miscellaneous Provisions

         6.1      Information Rights. The Company shall furnish to Shareholders:
(i) audited annual and unaudited quarterly financial statements; (ii) monthly
summary financial statements within twenty-one (21) days of the end of each
month; and (iii) a copy of Company's proposed annual business plan at least 45
days prior to the beginning of Company's fiscal year. Shareholders shall be
entitled to inspect books, records and properties of the Company on reasonable
notice and during normal business hours.

         6.2      Registration Rights.

                  a.       Demand Rights. If any Shareholder or Shareholders
                           holding at least five percent (5%) of the outstanding
                           Common Stock of the Company request in writing
                           (specifying that the request is being made pursuant
                           to this Section 6.2(a)) that the Company file a
                           registration statement or similar document under the
                           Securities Act to effect the registration of at least
                           fifteen percent (15%) of the Common Stock held by all
                           Shareholders (or any lesser percentage if the
                           aggregate offering price to the public would be not
                           less than $7,500,000, net of underwriting discounts
                           and commissions), the Company will, within ten (10)
                           days of receiving such request, provide notice to all
                           Shareholders of such request and shall use its best
                           efforts to effect the registration (including,
                           without limitation, filing post-effective amendments,
                           appropriate qualifications under applicable blue sky
                           or other state securities laws and ensuring
                           compliance with the Securities Act) of all shares of
                           Common Stock that any Shareholder joining in such
                           request shall specify in a written request received
                           by the Company within fifteen (15) days following
                           notice by the Company of the proposed registration.
                           The Company shall not be obligated to effect more
                           than two (2) registrations under these demand right
                           provisions for either Motorola or GMP, and shall not
                           be obligated to effect a registration (i) during the
                           one hundred eighty (180) day period commencing with
                           the date of a Qualified Public Offering, or (ii) if
                           it delivers notice to the holders of the shares of
                           Common Stock that have requested inclusion in such
                           registration within forty-five (45) days of receiving
                           any registration request of its intent to initiate
                           such Qualified Public Offering within one hundred
                           eighty (180) days.

                  b.       Company Registration. The Shareholders shall be
                           entitled to "piggyback" registration rights on all
                           registrations of the Company or on any demand

                                       11
<PAGE>   13

                           registrations of any other Shareholder.
                           Notwithstanding the foregoing, if the Board of
                           Directors of the Company determines, upon the advice
                           of the managing underwriter, that a limitation should
                           be imposed on the number of shares of Common Stock
                           which may be included in the registration statement
                           because, in its reasonable discretion, such
                           limitation is necessary to avoid a materially adverse
                           effect on the distribution or market for the Common
                           Stock, then the Company may exclude shares of Common
                           Stock pro rata among Shareholders seeking to include
                           shares of Common Stock, in proportion to the number
                           of shares of Common Stock owned by each such
                           Shareholder.

                  c.       S-3 Rights. Shareholders shall be entitled to two (2)
                           demand registrations on Form S-3 per year if
                           available to the Company so long as the aggregate
                           price to the public of such registered offerings are
                           not less than $500,000.

                  d.       Expenses. The Company shall bear registration
                           expenses (exclusive of underwriting discounts and
                           commissions) of all such demands, piggybacks and S-3
                           registrations.

                  e.       Transfer of Rights. The registration rights shall
                           inure to the benefit of a Permitted Transferee of a
                           Shareholder who is deemed a Shareholder hereunder in
                           accordance with Section 6.13 below, provided the
                           Company is given written notice thereof.

                  f.       Other Registration Rights.The Company shall not,
                           without the prior written consent of both the holders
                           of a majority of the Class A Common Stock and Class B
                           Common Stock, voting separately as a class, grant any
                           registration rights superior to or on parity with the
                           rights granted pursuant to this Section 6.2.

                  g.       Standoff Provision. No Shareholder of the Company
                           will sell shares within one hundred eighty (180) days
                           of the effective date of a Qualified Public Offering
                           if all officers, and directors are similarly bound.

                  h.       Other Provisions. Other provisions shall be entered
                           into with respect to registration rights as are
                           reasonable, including cross-indemnification, the
                           period of time in which the registration statement
                           shall be kept effective and underwriting
                           arrangements.

         6.3      No Right of Employment. No Shareholder shall have any right of
employment or other benefits, or any right to be a Director or officer of the
Company, solely as a consequence of owning Stock in the Company. Each
Shareholder who is a Director or officer of the Company acknowledges that, if
the Board of Directors determines that salary or other compensation (other than
dividends) shall be paid to any Director or officer of the Company, the Company
shall be under no obligation to pay each other Director or officer a
proportionate share of such salary or compensation.

                                       12
<PAGE>   14

         6.4      Company Designee. All rights granted to the Company by the
terms of this Agreement may be exercised by such person, persons, entity or
entities as the Board of Directors of the Company, in its sole discretion, shall
designate acting by vote or unanimous written consent.

         6.5      Endorsement of Stock Certificates. All certificates
representing Stock owned by the Shareholders shall have conspicuously endorsed
thereon a legend substantially as follows:

                              "TRANSFER RESTRICTED

                  THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO
                  CERTAIN RIGHTS AND CONDITIONS AND RESTRICTIONS UPON TRANSFER
                  PURSUANT TO A SHAREHOLDERS' AGREEMENT BY AND AMONG THE COMPANY
                  AND ITS SHAREHOLDERS. A COPY OF THE SHAREHOLDERS' AGREEMENT
                  MAY BE OBTAINED FROM THE COMPANY WITHOUT CHARGE UPON THE
                  WRITTEN REQUEST OF THE HOLDER HEREOF.

                  THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES
                  ACT OF 1933 OR ANY APPLICABLE STATE SECURITIES LAWS AND MAY
                  NOT BE TRANSFERRED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF
                  AN EFFECTIVE REGISTRATION STATEMENT COVERING SUCH SHARES UNDER
                  THAT ACT AND ANY APPLICABLE STATE SECURITIES LAWS, UNLESS, IN
                  THE OPINION OF COUNSEL SATISFACTORY TO THE COMPANY, AN
                  EXEMPTION FROM REGISTRATION THEREUNDER IS AVAILABLE."

         6.6      Entire Agreement. This Agreement together with the other
documents referenced herein represent the complete agreements among the parties
hereto with respect to the transactions contemplated hereby and supersedes all
prior written or oral agreements and understandings including without limitation
the March 29, 2000 Letter of Intent.

         6.7      Pronouns. Whenever the context of this Agreement permits, the
masculine gender shall include the feminine and neuter genders, and any
reference to the singular or plural shall be interchangeable with the other.

         6.8      Separability. The invalidity or unenforceability of any one or
more provisions of this Agreement shall not affect the other provisions hereof,
and this Agreement shall be construed in all respects as if any such invalid or
unenforceable provisions were omitted.

         6.9      Headings. The headings in this Agreement have been inserted
for convenience of reference only and shall not constitute a part of this
Agreement.

                                       13
<PAGE>   15

         6.10     Adjustments. If there shall be any change in the Stock of the
Company through merger, consolidation, reorganization, recapitalization, stock
dividend, stock split, anti-dilution addition, combination or exchange of
shares, or the like (any such event being an "Adjustment"), all of the terms and
provisions of this Agreement shall apply to any new, additional or different
shares or securities issued as a result of such Adjustment and the price and
number of securities subject to the provisions hereof shall be adjusted
accordingly.

         6.11     Notices. All notices, requests, demands, and other
communications under this Agreement shall be in writing and shall be deemed to
have been duly given on the date of service if served personally on the party to
whom notice is to be given, on the date of transmittal of services via telecopy
to the party to whom notice is to be given (with a confirming copy delivered
within 24 hours thereafter), or on the third day after mailing if mailed to the
party to whom notice is to be given, by first class mail, registered or
certified, postage prepaid, or via a nationally recognized overnight courier
providing a receipt for delivery and properly addressed as set forth below.

         For the Company:                     For GMP:

         Bart Chernow, M.D., President        Michael Salem, M.D.
         GMP|Wireless Medicine, Inc.          Executive Vice President
         One East Broward Blvd., Suite 1701   GMP|Companies, Inc.
         Fort Lauderdale, FL 33301            One East Broward Blvd., Suite 1701
                                              Fort Lauderdale FL 33301

         For Motorola:

         General Counsel
         Motorola, Inc.
         1301 East Algonquin Road
         Schaumburg, IL 60196

         Any party may change its address for purposes of this paragraph by
giving notice of the new address to each of the other parties in the manner set
forth above.

         6.12     Binding Effect. This Agreement shall be binding upon and inure
to the benefit of the parties hereto and their respective heirs,
representatives, successors and assigns.

         6.13     Parties. Any person who acquires ownership of Stock (including
shares of Stock hereafter issued) and who is required to become a party to this
Agreement in accordance with the terms of this Agreement shall automatically
become a party to this Agreement, as a Shareholder, and shall confirm such fact
by executing, upon request of any of the parties hereto, a counterpart of this
Agreement.

         6.14     Failure to Comply with the Provisions of this Agreement. In
addition to any other legal or equitable remedies which it or they may have, the
Company and the Shareholders may enforce their rights under any provision of
this Agreement by actions for specific performance (to

                                       14
<PAGE>   16

the extent permitted by law) and each party hereto acknowledges and agrees that
the parties hereto will be irreparably damaged in the event that this Agreement
is breached. Further, the Company may refuse to transfer on its books record
ownership of Stock that shall have been sold or transferred in violation of this
Agreement or to recognize any transferee as one of the Company's shareholders
for any purpose (including without limitation, for purposes of dividend and
voting rights) until all applicable provisions of this Agreement have been
complied with in full. All remedies provided by this Agreement are in addition
to other remedies provided by law.

         6.15     Waiver, Amendment and Termination. This Agreement may not be
amended or modified, and no provision hereof may be waived, without the written
consent of each Shareholder holding at least five (5%) of the shares of Stock
(on a fully diluted basis). This Agreement (other than Section 6.2 which shall
survive until (i) all of the shares of Common Stock held by a Shareholder have
been either sold or registered under the Securities Act, or (ii) all of such
shares of Common Stock may be sold under Rule 144 of the Securities Act without
regard to the volume limitations contained therein) shall terminate with respect
to all shares of Stock upon the closing of (a) a Qualified Public Offering, or
(b) a sale of all or substantially all of the assets or capital stock of the
Company, or (c) the consummation of any transaction in accordance with the
provisions of Section 2.1 hereof which results in a Change in Control. For the
purposes of this Agreement, a "Change in Control" shall be deemed to have
occurred if (i) the Company merges or consolidates with another entity and is
not the surviving entity (other than a merger to change the state of
incorporation of the Company or any successor entity); (ii) the Company sells or
otherwise transfers all or substantially all of its assets; or (iii) more than
50% of the voting capital stock of the Company is transferred in a single
transaction or a series of related transactions, provided, however, that any
increase in Motorola's equity ownership to an amount in excess of 50% shall not
be deemed a Change in Control for purposes of this Agreement.

         6.16     Counterparts. This Agreement may be executed in multiple
counterparts, each of which shall have the force and effect of an original and
all of which together shall constitute but one and the same document.

         6.17     Governing Law. This Agreement is executed and delivered in the
State of Delaware, and this Agreement shall be governed by and construed in
accordance with the laws of the State of Delaware for all purposes and in all
respects, without regard to the conflict of laws provisions of such state.

         6.18     Dispute Resolution. If the parties should have a material
dispute arising out of or relating to this Agreement or the parties' respective
rights and duties hereunder, then the affected parties will resolve such dispute
in the following manner: (i) any party may at any time deliver to the other
affected party a written dispute notice setting forth a brief description of the
issue for which such notice initiates the dispute resolution mechanism
contemplated by this Section 6.18; (ii) during the forty-five (45) day period
following the delivery of the notice described in Section 6.18(i) above,
appropriate representatives of the affected parties will meet and seek to
resolve the disputed issue through negotiation; and (iii) if representatives of
the parties are unable to resolve the disputed issue through negotiation, then
within thirty (30) days after the period described in Section 6.18(ii) above,
the parties will refer the issue (to the exclusion of a court of law) to final

                                       15
<PAGE>   17

and binding arbitration in Wilmington, Delaware in accordance with the then
existing rules (the "Rules") of the American Arbitration Association ("AAA"),
and judgment upon the award rendered by the arbitrators may be entered in any
court having jurisdiction thereof; provided, however, that the law applicable to
any controversy shall be the law of the State of Delaware, regardless of
principles of conflicts of laws. In any arbitration pursuant to this Agreement,
(i) discovery shall be allowed and governed by the Delaware Code of Civil
Procedure and (ii) the award or decision shall be rendered by a majority of the
members of a Board of Arbitration consisting of three (3) members, one of whom
shall be appointed by each of the respective parties and the third of whom shall
be the chairman of the panel and shall be appointed by mutual agreement of said
two party-appointed arbitrators. In the event of failure of said two arbitrators
to agree within thirty (30) calendar days after the commencement of the
arbitration proceeding upon the appointment of the third arbitrator, the third
arbitrator shall be appointed by the AAA in accordance with the Rules. In the
event that either party shall fail to appoint an arbitrator within ten (10)
calendar days after the commencement of the arbitration proceedings, such
arbitrator and the third arbitrator shall be appointed by the AAA in accordance
with the Rules. Nothing set forth above shall be interpreted to prevent the
parties from agreeing in writing to submit any dispute to a single arbitrator in
lieu of a three (3) member Board of Arbitration. Upon the completion of the
selection of the Board of Arbitration (or if the parties agree otherwise in
writing, a single arbitrator), an award or decision shall be rendered within no
more than forty-five (45) days. Notwithstanding the foregoing, the request by
either party for preliminary or permanent injunctive relief, whether prohibitive
or mandatory, shall not be subject to arbitration and may be adjudicated only by
the courts of the State of Delaware or the U.S. District Courts in Delaware.

                                       16
<PAGE>   18

         IN WITNESS WHEREOF, the Company and the Shareholders have executed this
Shareholders' Agreement as of the day and year first above written.

THE COMPANY:                                GMP:

GMP|Wireless Medicine, Inc.                 GMP|Companies, Inc.

By:                                         By:
   ---------------------------------           ---------------------------------
Bart Chernow, M.D., President               Michael Salem, M.D.,
                                            Executive Vice President
One East Broward Blvd., Suite 1701          One East Broward Blvd., Suite 1701
Fort Lauderdale, FL 33301                   Fort Lauderdale FL 33301
Facsimile: 954-745-3511                     Facsimile: 954-745-3511

MOTOROLA:

Motorola, Inc.

By:
   ---------------------------------
Jonathan Meyer
Senior Vice President,
Assistant General Counsel,
and n   Director of Patents,
Trademarks and Licensing

1301 East Algonquin Road
Schaumburg, IL 60196
Facsimile:
          --------------------------

                                       17

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00016-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00016-of-00352.parquet"}]]